6300-94-3

Usage

Uses

Used in Pharmaceutical Industry:
6,6-diMethyldihydropyriMidine-2,4(1H,3H)-dione is used as a key intermediate in the synthesis of pharmaceuticals for its potential role in the development of new drugs. Its unique properties allow it to be a building block in organic synthesis, contributing to the creation of innovative medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 6,6-diMethyldihydropyriMidine-2,4(1H,3H)-dione is utilized as an intermediate in the production of various agrochemicals, playing a crucial part in the synthesis of compounds that can enhance crop protection and yield.
Used in Organic Synthesis:
6,6-diMethyldihydropyriMidine-2,4(1H,3H)-dione is used as a building block in organic synthesis, particularly for the development of novel chemical entities with potential applications in various fields, including material science and specialty chemicals.
Used in Molecular Recognition and Supramolecular Chemistry:
Due to its ability to form hydrogen-bonded complexes, 6,6-diMethyldihydropyriMidine-2,4(1H,3H)-dione is employed in the study of molecular recognition and supramolecular chemistry, aiding in the understanding of molecular interactions and the design of new complex systems.

InChI:InChI=1/C6H10N2O2/c1-6(2)3-4(9)7-5(10)8-6/h3H2,1-2H3,(H2,7,8,9,10)

Upstream product

• 541-47-9 3-Methylbutenoic acid 
• 57-13-6 urea 
• 72054-54-7 3-Methyl-3-ureido-butyric acid 

Downstream Products

• 51219-55-7 3-(benzyloxycarbonylamino)-3-methylbutanoic acid 
• 914939-77-8 3-methyl-3-(methyl{[(phenylmethyl)oxy]carbonyl}amino)butanoic acid 
• 914939-76-7 phenylmethyl 4,4-dimethyl-6-oxo-1,3-oxazinane-3-carboxylate 
• 625-05-8 3-amino-3-methylbutanoic acid 

Relevant academic research and scientific papers

Effective methods for the synthesis of N-methyl β-amino acids from all twenty common α-amino acids using 1,3-oxazolidin-5-ones and 1,3-oxazinan-6-ones

N-Methyl β-amino acids are generally required for application in the synthesis of potentially bioactive modified peptides and other oligomers. Previous work highlighted the reductive cleavage of 1,3-oxazolidin-5-ones to synthesise N-methyl α-amino acids. Starting from α-amino acids, two approaches were used to prepare the corresponding N-methyl β-amino acids. First, α-amino acids were converted to N-methyl α-amino acids by the so-called '1,3-oxazolidin-5-one strategy', and these were then homologated by the Arndt-Eistert procedure to afford N-protected N-methyl β-amino acids derived from the 20 common α-amino acids. These compounds were prepared in yields of 23-57% (relative to N-methyl α-amino acid). In a second approach, twelve N-protected α-amino acids could be directly homologated by the Arndt-Eistert procedure, and the resulting β-amino acids were converted to the 1,3-oxazinan-6-ones in 30-45% yield. Finally, reductive cleavage afforded the desired N-methyl β-amino acids in 41-63% yield. One sterically congested β-amino acid, 3-methyl-3-aminobutanoic acid, did give a high yield (95%) of the 1,3-oxazinan-6-one (65), and subsequent reductive cleavage gave the corresponding AIBN-derived N-methyl β-amino acid 61 in 71% yield (Scheme 2). Thus, our protocols allow the ready preparation of all N-methyl β-amino acids derived from the 20 proteinogenic α-amino acids.

Synthesis of new β-amino acids via 5-oxazolidinones and the arndt-eistert procedure

N-Methyl β-amino acids are potentially useful amino acid derivatives for incorporation in lead peptide therapeutics. The syntheses of five such compounds are presented. Their synthesis via 6-oxazinanones was low yielding. Alternatively, reductive cleavage of a 5-oxazolidinone gave the N-methyl β-amino acid, which was then homologated via an Arndt-Eistert procedure in high yield to give the N-methyl α-amino acid. CSIRO 2005.